Literature DB >> 18957896

Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis.

Alexander Sarlette1, Klaus Krampfl, Claudia Grothe, Nils von Neuhoff, Reinhard Dengler, Susanne Petri.   

Abstract

Oxidative stress and inflammation are important pathogenetic mechanisms in amyotrophic lateral sclerosis (ALS). Nuclear erythroid 2-related factor 2 (Nrf2) is a basic region leucine-zipper transcription factor that binds to the antioxidant response element, thereby regulating the expression of many genes that are involved in cellular antioxidant and anti-inflammatory defense. Under normal conditions, Nrf2 activation is inhibited by Kelch-like ECH-associated protein 1 (Keap1). We investigated the potential involvement of the Nrf2/antioxidant response element signaling pathway in the selective degeneration of motor neurons in ALS. Nrf2 and Keap1 expression was analyzed in primary motor cortex and spinal cord postmortem tissue samples from ALS patients and controls by in situ hybridization histochemistry, quantitative real-time polymerase chain reaction, immunohistochemistry, and Western blot analysis. In ALS samples, there was a reduction of Nrf2 mRNA and protein expression in neurons, whereas Keap1 mRNA expression was increased in the motor cortex. These results suggest that alterations in this signaling cascade occur in motor neurons in ALS and that they may contribute to chronic motor neuron degeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18957896     DOI: 10.1097/NEN.0b013e31818b4906

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  58 in total

Review 1.  The Nrf2-ARE cytoprotective pathway in astrocytes.

Authors:  Marcelo R Vargas; Jeffrey A Johnson
Journal:  Expert Rev Mol Med       Date:  2009-06-03       Impact factor: 5.600

2.  RBM45 Modulates the Antioxidant Response in Amyotrophic Lateral Sclerosis through Interactions with KEAP1.

Authors:  Nadine Bakkar; Arianna Kousari; Tina Kovalik; Yang Li; Robert Bowser
Journal:  Mol Cell Biol       Date:  2015-05-04       Impact factor: 4.272

3.  The Nrf2-inducible antioxidant defense in astrocytes can be both up- and down-regulated by activated microglia:Involvement of p38 MAPK.

Authors:  Fernando Correa; Elin Ljunggren; Carina Mallard; Michael Nilsson; Stephen G Weber; Mats Sandberg
Journal:  Glia       Date:  2011-02-23       Impact factor: 7.452

Review 4.  The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Gururaj Joshi; Jeffrey A Johnson
Journal:  Recent Pat CNS Drug Discov       Date:  2012-12

Review 5.  Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis.

Authors:  Laura Ferraiuolo; Janine Kirby; Andrew J Grierson; Michael Sendtner; Pamela J Shaw
Journal:  Nat Rev Neurol       Date:  2011-11       Impact factor: 42.937

Review 6.  Redox-based therapeutics in neurodegenerative disease.

Authors:  G J McBean; M G López; F K Wallner
Journal:  Br J Pharmacol       Date:  2016-08-25       Impact factor: 8.739

Review 7.  Stress-activated cap'n'collar transcription factors in aging and human disease.

Authors:  Gerasimos P Sykiotis; Dirk Bohmann
Journal:  Sci Signal       Date:  2010-03-09       Impact factor: 8.192

Review 8.  Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection.

Authors:  Meijuan Zhang; Chengrui An; Yanqin Gao; Rehana K Leak; Jun Chen; Feng Zhang
Journal:  Prog Neurobiol       Date:  2012-09-29       Impact factor: 11.685

Review 9.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

10.  COP9 limits dendritic branching via Cullin3-dependent degradation of the actin-crosslinking BTB-domain protein Kelch.

Authors:  Inna Djagaeva; Sergey Doronkin
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.